Know Cancer

or
forgot password

A Phase I/II Trial of Recombinant Human Thrombopoietin in Children With Malignant Solid Tumors and Lymphoma Receiving Ifosfamide, Carboplatin and Etoposide


Phase 1/Phase 2
N/A
21 Years
Not Enrolling
Both
Germ Cell Tumors, Hepatic Cancer, Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma

Thank you

Trial Information

A Phase I/II Trial of Recombinant Human Thrombopoietin in Children With Malignant Solid Tumors and Lymphoma Receiving Ifosfamide, Carboplatin and Etoposide


Inclusion Criteria:



- Diagnosis of recurrent, refractory, or previously untreated malignant solid tumor or
recurrent/refractory lymphoma for which Ifosfamide, Carboplatin, and Etoposide
chemotherapy is the most appropriate treatment.

- Adequate liver and kidney function.

- Adequate performance status.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaluate the safety of recombinant human thrombopoietin following chemotherapy which includes ifosfamide, carboplatin and etoposide for solid tumors and lymphoma.

Principal Investigator

Najat C. Daw, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

St. Jude Children's Research Hospital

Authority:

United States: Food and Drug Administration

Study ID:

TPO

NCT ID:

NCT00187109

Start Date:

June 2000

Completion Date:

February 2007

Related Keywords:

  • Germ Cell Tumors
  • Hepatic Cancer
  • Neuroblastoma
  • Osteosarcoma
  • Rhabdomyosarcoma
  • Thrombocytopenia
  • Platelets
  • Thrombopoietin
  • Liver Neoplasms
  • Neuroblastoma
  • Osteosarcoma
  • Rhabdomyosarcoma
  • Neoplasms, Germ Cell and Embryonal

Name

Location

St. Jude Children's Research HospitalMemphis, Tennessee  38105-2794